1. Introduction 1.1 Market Definition 2. Research Methodology 3. Executive Summary 4. Key Inferences 5. Market Overview 5.1 Current Market Scenario 5.2 Porter's Five Forces Analysis 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Consumers 5.2.3 Threat of New Entrants 5.2.4 Threat of Substitute Product and Services 5.2.5 Competitive Rivalry within the Industry 6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC) 6.1 Market Drivers 6.1.1 Growing Obesity and Diabetes Prevalence Worldwide 6.1.2 Strong R&D investment from Key Players Offering Promising Molecules Increasing the Patient Base 6.1.3 Extensive & Well-established Distribution Network of Insulin Drugs 6.1.4 Biologics Going Off-Patent 6.2 Market Restraints 6.2.1 High Out-of-Pocket and Low Healthcare Expenditure on Diabetes 6.2.2 Highly Competitive Market Leading to Increasing Pricing Pressure 6.3 Opportunities 6.4 Key Challenges 7. Market Segmentation 7.1 By Product Type 7.1.1 Short-acting Insulin 7.1.2 Intermediate-acting Insulin 7.1.3 Long-acting Insulin 7.1.4 Premixed Insulin 7.2 By Drug Type 7.2.1 Generic Drugs 7.2.2 Branded Drugs 7.3 By Disease Type 7.3.1 Type 1 Diabetes 7.3.2 Type 2 Diabetes 7.4 By Geography 7.4.1 North America 7.4.1.1 United States 7.4.1.2 Canada 7.4.1.3 Mexico 7.4.2 Europe 7.4.2.1 France 7.4.2.2 Germany 7.4.2.3 United Kingdom 7.4.2.4 Italy 7.4.2.5 Spain 7.4.2.6 Rest Of Europe 7.4.3 Asia-Pacific 7.4.3.1 China 7.4.3.2 Japan 7.4.3.3 India 7.4.3.4 Australia & New Zealand 7.4.3.5 South Korea 7.4.3.6 Rest of Asia-Pacific 7.4.4 Middle East & Africa 7.4.4.1 GCC 7.4.4.2 South Africa 7.4.4.3 Rest of the Middle East & Africa 7.4.5 South America 7.4.5.1 Brazil 7.4.5.2 Argentina 7.4.5.3 Rest of South America 8. Competitive Landscape 8.1 Mergers & Acquisition Analysis 8.2 Agreements, Collaborations, and Partnerships 8.3 New Products Launches 9. Key Players 9.1 AstraZeneca PLC 9.2 Biocon 9.3 Bioton S.A. 9.4 Eli Lilly and Company 9.5 Julphar 9.6 Merck & Co., Inc. 9.7 Novo Nordisk A/S 9.8 Teva Pharmaceutical Industries Ltd 9.9 Sanofi-Aventis 9.10 Wockhardt Ltd 9.11 Others 10. Future of the Market

ASTRAZENECA, BIOCON, BIOTON S.A., ELI LILLY AND COMPANY, JULPHAR, MERCK & CO., INC., NOVO NORDISK A/S, TEVA PHARMACEUTICAL INDUSTRIES LTD, SANOFI-AVENTIS, AND WOCKHARDT LTD,